Assembly Biosciences, Inc.

Contributing Author

Recent Articles by Assembly Biosciences, Inc.

May-22	Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants ASMB +6.94% GlobeNewswire
May-22	Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases ASMB +6.94% GlobeNewswire
May-13	Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026 ASMB GlobeNewswire
May-11	Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference ASMB GlobeNewswire
May-07	Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights ASMB GlobeNewswire
Apr-09	Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026 ASMB GlobeNewswire
Mar-19	Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights ASMB GlobeNewswire
Dec-08	Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes ASMB GlobeNewswire
Nov-10	Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates ASMB GlobeNewswire
Nov-07	Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting ASMB GlobeNewswire
Oct-14	Assembly Biosciences Announces Upcoming Investor Conference Participation ASMB GlobeNewswire
Oct-10	Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe ASMB GlobeNewswire
Aug-08	Assembly Biosciences Announces Pricing of $175 Million in Equity Financings ASMB +12.96% GlobeNewswire
Aug-08	Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes ASMB +12.96% GlobeNewswire
Aug-06	Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus ASMB +9.21% ASMB GlobeNewswire
Aug-06	Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates ASMB +9.21% ASMB GlobeNewswire
Jul-26	Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop ASMB GlobeNewswire
Jun-30	Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179 ASMB GlobeNewswire
Jun-25	Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B ASMB GlobeNewswire
May-27	Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference ASMB GlobeNewswire
May-08	Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates ASMB -6.04% GlobeNewswire
May-07	New Preclinical Data for Assembly Biosciences' Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025 ASMB GlobeNewswire

Assembly Biosciences, Inc.

Recent Articles by Assembly Biosciences, Inc.

Upgrade your Finviz experience